

Lymphoma/leukemia diagnosis for targeted therapy, 2019

Lymphoma diagnosis and targeted treatment is challenged by the introduction of new drugs and refinements in the definition of new entities. This FJD Symposium will cover new markers and opportunities for a precision lymphoma/leukemia medicine

Nov 21-22nd, 2018

Fundación Jiménez Díaz Madrid

Provisional program (v13)

Nov 21st

1000-1015: F Rojo/P Llamas/C Ayuso (FJD): Welcome and Meeting introduction

**1015-1045: B Pro (Northwestern University Feinberg School of Medicine Chicago):
Advances in T-cell lymphoma treatment**

1045-1200: Clinical case discussion Forum

- 1. P Ortiz (12O): New approved treatments for CTCL (MF/SS)**
- 2. SM Rodriguez-Pinilla (FJD): Subcutaneous Panniculitic T-cell lymphoma**
- 3. R Córdoba (FJD): T-cell lymphoma therapy**
- 4. D Morillo, A Trascasa (FJD): TP53+ CLL, the relevance of the clonal evolution**

1200-1230: Café

1230-1300: F Fend: Bone marrow biopsy in the diagnosis of myeloid disorders

1300-1400: Clinical case discussion Forum

- 1. F Climent (Hospital Universitario de Bellvitge) : chronic eosinophilic leukemia with PDGFRA rearrangement**
- 2. F Fend (University Hospital Tuebingen) : Histiocytic and dendritic cell neoplasms**
- 3. J Menarguez, JL Diaz-Crespo, M Bastos (HUGM): CAR-T cell therapy**
- 4. C Santonja, F Lobo (FJD): BIA-ALCL**

1400-1500: Lunch

1500-1530: Guillermo Garcia-Manero (MDACC Houston): Breaking Myelodysplastic Syndrome

1530-1600: Juan Manuel Alonso Dominguez (FJD): Molecular developments in diagnosis and therapeutics of AML

1600-1745: Clinical case discussion Forum

- 1. G Garcia-Manero: NPM1 mutations define a specific subgroup of MD: and MDS/MPN patients with favorable outcomes with intensive chemotherapy**

2. P Dominguez (HURJC): HHV8 associated disorders
3. J Sanchez Garcia (HGV): Breast-implant associated lymphoma
4. M Mollejo (HVS): MYD88 mutated B-cell lymphomas
5. I Betancurt (FJD): Follicular lymphoma with Hodgkin features
6. M Garcia, L Prieto (HCU Lozano Blesa, Zaragoza): Granulomatous dermatitis associated with CMML
7. G Olmedilla, M Gasier (H La Paz): Follicular lymphoma, blastoid

Nov 22nd

0900-0930: PL Zinzani (University of Bologna), The role of checkpoint inhibitors in non-Hodgkin lymphoma

0930-1100: Clinical case discussion Forum

1. C Bárcena, JM Sánchez-Pina (H12O): Diffuse Large B-Cell Lymphoma Treated with CAR-T Cells: Clinical and pathological effects
2. M Rodriguez-Moreno (FJD): T-cell lymphoma signatures
3. M Sanchez-Beato (HPdH): Mutational spectrum in R-CHOP resistant DLBCL
4. M Piris (FJD): Mediastinal large B-cell lymphoma
5. D Morillo, I Betencour (FJD): Cutaneous reaction after checkpoint inhibitors
6. M Jo (FJD): Childhood cutaneous marginal zone B-cell lymphoma

1100-1130: Café

1130-1200: D Rossi (Istituto Oncologico della Svizzera Italiana (IOSI)): Liquid biopsy in lymphoma diagnosis and follow-up

1200-1300: Clinical case discussion Forum

1. JF García (MDACC): Liquid biopsy in T-cell lymphoma
2. S Montes-Moreno: Liquid biopsy in Large B-cell Lymphoma
3. D Rossi: Splenic marginal zone B-cell lymphoma
4. G Salvatierra, P Dominguez, Hodgkin lymphoma

1300-1330: R Córdoba/SM Rodríguez-Pinilla (FJD): REAL-T Study

Clinical case discussion Forum

Instructive lymphoma/leukemia cases presented by both clinicians and pathologists will be discussed along 5 different sessions

In total more than 6 hrs. In principle, 25 cases will be selected from submitted proposals

Cases are expected to cover new areas of lymphoma/leukemia diagnosis and targeted treatment

Scientific Committee: P LLAMAS, F ROJO, M PIRIS, SM RODRIGUEZ-PINILLA, R CORDOBA



Sociedad Española de
Hematología y Hemoterapia



ciberonc iscii

Unión Europea
Fondo Social Europeo
El FSE invierte en tu futuro



aecc
Centro de Cáncer